Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors.

Waterson AG, Petrov KG, Hornberger KR, Hubbard RD, Sammond DM, Smith SC, Dickson HD, Caferro TR, Hinkle KW, Stevens KL, Dickerson SH, Rusnak DW, Spehar GM, Wood ER, Griffin RJ, Uehling DE.

Bioorg Med Chem Lett. 2009 Mar 1;19(5):1332-6. doi: 10.1016/j.bmcl.2009.01.080. Epub 2009 Feb 7.

PMID:
19208477
2.

Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.

Rheault TR, Caferro TR, Dickerson SH, Donaldson KH, Gaul MD, Goetz AS, Mullin RJ, McDonald OB, Petrov KG, Rusnak DW, Shewchuk LM, Spehar GM, Truesdale AT, Vanderwall DE, Wood ER, Uehling DE.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):817-20. doi: 10.1016/j.bmcl.2008.12.011. Epub 2008 Dec 7.

PMID:
19111461
3.

Discovery of thiophene inhibitors of polo-like kinase.

Emmitte KA, Andrews CW, Badiang JG, Davis-Ward RG, Dickson HD, Drewry DH, Emerson HK, Epperly AH, Hassler DF, Knick VB, Kuntz KW, Lansing TJ, Linn JA, Mook RA Jr, Nailor KE, Salovich JM, Spehar GM, Cheung M.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):1018-21. doi: 10.1016/j.bmcl.2008.11.041. Epub 2008 Nov 18.

PMID:
19097784
4.

Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.

Gilmer TM, Cable L, Alligood K, Rusnak D, Spehar G, Gallagher KT, Woldu E, Carter HL, Truesdale AT, Shewchuk L, Wood ER.

Cancer Res. 2008 Jan 15;68(2):571-9. doi: 10.1158/0008-5472.CAN-07-2404.

5.

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.

Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws TF Jr, Hudson-Curtis BL, Gilmer TM.

Cell Prolif. 2007 Aug;40(4):580-94.

PMID:
17635524
6.

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.

Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, Noro N, Furuta M, Emmitte KA, Gilmer TM, Mook RA Jr, Cheung M.

Mol Cancer Ther. 2007 Feb;6(2):450-9. Epub 2007 Jan 31.

7.

Strain dependence of the cell wall-damage induced stimulon in Staphylococcus aureus.

McCallum N, Spehar G, Bischoff M, Berger-B├Ąchi B.

Biochim Biophys Acta. 2006 Oct;1760(10):1475-81. Epub 2006 Jul 1.

PMID:
16891058
8.

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ.

Cancer Res. 2006 Feb 1;66(3):1630-9.

9.

A fluorescent-based assay for measurement of phospholipase A2 activity. A facile assay for cell sonicates.

Nicotera TM, Spehar G.

Methods Mol Biol. 1998;108:211-6. No abstract available.

PMID:
9921531

Supplemental Content

Loading ...
Support Center